<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00645411</url>
  </required_header>
  <id_info>
    <org_study_id>V58P12</org_study_id>
    <secondary_id>Eudract Number: 2007-001534-13</secondary_id>
    <nct_id>NCT00645411</nct_id>
  </id_info>
  <brief_title>Pediatric Safety and Immunogenicity Study of Cell-Culture Derived and Egg-based Subunit Influenza Vaccines in Healthy Children and Adolescents</brief_title>
  <official_title>A Combined Phase II/III, Observer-Blind, Randomized, Multi-center Study to Evaluate Safety, Tolerability and Immunogenicity of Trivalent Subunit Influenza Vaccines, Produced Either in Mammalian Cell Culture or in Embryonated Hen Eggs, in Healthy Children and Adolescents</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis Vaccines</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present study is the first study designed to evaluate safety, tolerability and
      immunogenicity of the cell culture-derived influenza vaccine in healthy children and
      adolescents aged 3 to 17 years. A step-down approach is utilized in which reactogenicity and
      safety will be assessed in children and adolescents 9 to 17 years of age (Cohort 1) prior to
      enrolling additional children and adolescents 9 to 17 years of age (Cohort 2) and children 3
      to 8 years of age (Cohort 3).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">July 2008</completion_date>
  <primary_completion_date type="Actual">February 2008</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Geometric Mean Titers of the Cell Culture-derived Vaccine Compared With the Egg-derived Vaccine in 3 to 8 Year-old Children</measure>
    <time_frame>Day 50 post vaccination</time_frame>
    <description>To demonstrate non-inferiority of the post vaccination hemagglutination inhibition (HI) geometric mean titer (GMT) of the cell culture-derived influenza (cTIV) vaccine to the corresponding GMT of the egg-derived (eTIV) influenza vaccine, for all three strains, after two injections administered four weeks apart to a subset of children 3 to 8 years of age.
GMTs were evaluated using two assays, HI egg derived antigen assay and HI cell derived antigen assay.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentages of Subjects Who Attained Seroconversion or Significant Increase in Antibody Titers in the Cell Culture-derived Vaccine Compared With the Egg-derived Vaccine in 3 to 8 Year-old Children</measure>
    <time_frame>Day 50 post vaccination</time_frame>
    <description>To demonstrate non-inferiority of the cell culture-derived influenza (cTIV) vaccine to the egg-derived (eTIV) influenza vaccine in the percentage of subjects achieving seroconversion or significant increase in antibody titer post vaccination, for all three strains, after two injections administered four weeks apart in children 3 to 8 years of age.
Seroconversion rate was evaluated using two assays- HI egg derived antigen assay and HI cell derived antigen assay.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titers After 1 Dose of the Cell Culture-derived or the Egg-derived Influenza Vaccine in 9 to 17 Year-old Children and Adolescents</measure>
    <time_frame>Day 29 post vaccination</time_frame>
    <description>To evaluate immunogenicity in terms of Geometric Mean Titers (GMTs) in children 9 to 17 years of age after one injection of either cTIV vaccine or eTIV.
GMTs were evaluated using two assays, HI egg derived antigen assay and HI cell derived antigen assay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Ratio After 1 Dose of the Cell Culture-derived or the Egg-derived Influenza Vaccine in 9 to 17 Year-old Children and Adolescents.</measure>
    <time_frame>Day 29 post vaccination</time_frame>
    <description>Immunogenicity was evaluated in terms of Geometric Mean Ratio (GMRs) in 9 to 17 year-old children and adolescents after one injection of either cTIV vaccine or eTIV.
The criterion is met according to European (CHMP) guideline if the mean geometric increase GMR (day29/day1) in HI antibody titer is &gt;2.5.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentages of Subjects Who Achieved HI Titers ≥40 After 1 Dose of the Cell Culture-derived Vaccine or the Egg-derived Influenza Vaccine in 9 to 17 Year-old Children and Adolescents</measure>
    <time_frame>Day 29 post vaccination</time_frame>
    <description>To evaluate immunogenicity in terms of percentage of 9 to 17 year-old children and adolescents achieving HI titers ≥40, after one injection of either the cTIV vaccine or the eTIV vaccine.
This criterion is met according to European (CHMP) guideline if the percentage of subjects achieving HI titers ≥40 is &gt;70% and according to the US (CBER) guideline is met if the lower bound of the two sided 95%CI for percentage of subjects achieving HI titers ≥40 is ≥70%.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentages of Subjects Who Attained Seroconversion or Significant Increase After 1 Dose of the Cell Culture-derived Vaccine or the Egg-derived Influenza Vaccine in 9 to 17 Year-old Children and Adolescents</measure>
    <time_frame>Day 29 post vaccination</time_frame>
    <description>Seroconversion or significant increase as per CHMP criteria is defined as percentage of subjects with a pre vaccination HI titer &lt;10 to a post vaccination titer ≥40 or a pre vaccination HI titer ≥10 and a ≥4-fold increase in post vaccination HI antibody titer. According to the CHMP criteria, the percentage of subjects achieving seroconversion or significant increase should be &gt;40%.
According to the CBER criteria, the lower bound of the two-sided 95% CI for the percentage of subjects achieving seroconversion/significant increase should be ≥40%.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titers After Two Doses of the Cell Derived or the Egg Derived Vaccine in 3 to 8 Year-old Children</measure>
    <time_frame>Day 29 and Day 50 post vaccination</time_frame>
    <description>To evaluate immunogenicity in terms of Geometric Mean Titers (GMTs) in children 3 to 8 years of age after two doses of either cTIV vaccine or eTIV,administered 4 weeks apart.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Ratio After Two Doses of the Cell-derived or the Egg-derived Vaccine in 3 to 8 Year-old Children</measure>
    <time_frame>Day 29 and Day 50 post vaccination</time_frame>
    <description>To evaluate immunogenicity in terms of Geometric Mean Ratio (GMR) in children 3 to 8 years of age after two doses of either the cTIV vaccine or the eTIV vaccine, administered 4 weeks apart according to the CHMP criteria.
The criterion is met according to the European (CHMP) guideline if the mean geometric increase (GMR day 29/day 1 and GMR day 50/day 1) in HI antibody titer is &gt;2.5</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentages of Subjects Who Achieved HI Titers ≥40 After Two Doses of the Cell Culture Derived or the Egg Derived Influenza Vaccine in 3 to 8 Year-old Children</measure>
    <time_frame>Day 29 and Day 50 post vaccination</time_frame>
    <description>To evaluate immunogenicity in terms of HI titers ≥40, in children 3-8 years of age after two doses of either cTIV vaccine or eTIV vaccine, administered 4 weeks apart.
The criterion is met according to European (CHMP) guideline if the percentage of subjects achieving HI titers ≥40 is &gt;70% and according to the US (CBER) guideline if the lower bound of the two sided 95%CI for percentage of subjects achieving HI titers ≥40 is ≥70%.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentages of Subjects Who Achieved Seroconversion or Significant Increase in HI Titers After Two Doses of the Cell Culture-derived Vaccine or the Egg-derived Influenza Vaccine in 3 to 8 Year-old Children</measure>
    <time_frame>Day 29 and Day 50 post vaccination</time_frame>
    <description>Seroconversion or significant increase as per CHMP criteria is defined as percentage of subjects with a pre vaccination HI titer &lt;10 to a post vaccination titer ≥40 or a pre vaccination HI titer ≥10 and a ≥4-fold increase in post vaccination HI antibody titer. According to the CHMP criteria, the percentage of subjects achieving seroconversion or significant increase should be &gt;40%.
According to the CBER criteria, the lower bound of the two-sided 95% CI for the percentage of subjects achieving seroconversion/significant increase should be ≥40%.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Local and Systemic Reactions After 1 Dose of the Cell Culture-derived or the Egg-derived Influenza Vaccine in 9 to 17 Year-old Children and Adolescents.</measure>
    <time_frame>up to 7 days after vaccination</time_frame>
    <description>To evaluate safety and tolerability in terms of number of 9 to 17 year-old children and adolescents (cohorts 1 and 2) reporting local and systemic reactions following of one injection of the cTIV or the eTIV vaccine .</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Local and Systemic Reactions After One and Two Doses of the Cell Culture-derived Vaccine or Egg-derived Influenza Vaccine in 3 to 8 Year-old Children.</measure>
    <time_frame>up to 7 days after each vaccination</time_frame>
    <description>To evaluate the safety and tolerability of the cTIV and the eTIV influenza vaccines in 3 to 8 year-old children terms of number of participants reporting local and systemic reactions after each vaccination.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">3604</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>Cohorts 1 + Cohort 2 (9-17 Yrs) cTIV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All subjects received one 0.5 mL IM injection, of cell culture-derived trivalent influenza vaccine containing 15μg of HA for each strain (A/Solomon Islands/3/2006 [H1N1]-like, A/Wisconsin/67/2005 [H3N2]-like, and B/Malaysia/ 2506/2004-like), recommended for the 2007-2008 influenza season in the Northern Hemisphere</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohorts 1 + Cohort 2 (9-17 Yrs) eTIV</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>All subjects received one 0.5 mL injection, of egg -derived trivalent influenza vaccine containing 15μg of HA for each strain (A/Solomon Islands/3/2006 [H1N1]-like, A/Wisconsin/67/2005 [H3N2]-like and B/Malaysia/ 2506/2004-like), recommended for the 2007-2008 influenza season in the Northern Hemisphere.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3 (3-8 Yrs) cTIV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All subjects received two 0.5 mL injections, administered four weeks apart, of cell culture-derived trivalent influenza vaccine containing 15μg of HA for each strain (A/Solomon Islands/3/2006 [H1N1]-like, A/Wisconsin/67/2005 [H3N2]-like and B/Malaysia/ 2506/2004-like), recommended for the 2007-2008 influenza season in the Northern Hemisphere</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3 (3-8 Yrs) eTIV</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>All subjects received two 0.5 mL injections, administered four weeks apart of egg -derived trivalent influenza vaccine containing 15μg of HA for each strain (A/Solomon Islands/3/2006 [H1N1]-like, A/Wisconsin/67/2005 [H3N2]-like and B/Malaysia/ 2506/2004-like), recommended for the 2007-2008 influenza season in the Northern Hemisphere</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Cell culture-derived influenza subunit vaccine (cTIV)</intervention_name>
    <description>One 0.5 ml injection of the cell culture-derived influenza vaccine in the deltoid muscle, preferably of the nondominant arm.</description>
    <arm_group_label>Cohorts 1 + Cohort 2 (9-17 Yrs) cTIV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Egg derived influenza subunit vaccine (eTIV)</intervention_name>
    <description>One 0.5 ml injection of the conventional egg-derived influenza vaccine in the deltoid muscle, preferably of the nondominant arm.</description>
    <arm_group_label>Cohorts 1 + Cohort 2 (9-17 Yrs) eTIV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Cell culture-derived influenza subunit vaccine (cTIV)</intervention_name>
    <description>Two 0.5 mL injections,of the cell culture-derived influenza vaccine in the deltoid muscle, preferably of the nondominant arm, administered four weeks apart.</description>
    <arm_group_label>Cohort 3 (3-8 Yrs) cTIV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Egg derived influenza subunit vaccine (eTIV)</intervention_name>
    <description>Two 0.5 mL injections of the conventional egg-derived influenza vaccine in the deltoid muscle, preferably of the nondominant arm,administered four weeks apart.</description>
    <arm_group_label>Cohort 3 (3-8 Yrs) eTIV</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjects aged 9 to 17 years (Cohorts 1 and 2) and 3 to 8 years (Cohort 3), whose
             parents/legal guardians have given written informed consent prior to study entry.
             Assent will be obtained from subjects according to age requirements of the ECs/IRBs;

          2. In good health as determined by:

               1. medical history,

               2. physical examination,

               3. clinical judgment of the Investigator;

          3. Able to comply with all study procedures and available for all clinic visits and
             telephone calls scheduled in the study.

        Exclusion Criteria:

          1. Any serious disease, such as:

               1. cancer,

               2. autoimmune disease (including rheumatoid arthritis),

               3. diabetes mellitus,

               4. chronic pulmonary disease,

               5. acute or progressive hepatic disease,

               6. acute or progressive renal disease;

          2. History of any anaphylaxis or serious reaction following administration of vaccine, or
             hypersensitivity to eggs, egg protein, chicken feathers, influenza viral protein,
             neomycin, polymyxin, or any other vaccine component, chemically related substance, or
             component of the potential packaging materials;

          3. Known or suspected impairment/alteration of immune function, including:

               1. use of immunosuppressive therapy such as systemic corticosteroids known to be
                  associated with the suppression of hypothalamic-pituitary-adrenal (HPA) axis or
                  chronic use of inhaled high-potency corticosteroids within 60 days prior to Visit
                  1,

               2. cancer chemotherapy,

               3. receipt of immunostimulants within 60 days prior to Visit 1,

               4. receipt of parenteral immunoglobulin preparation, blood products, and/or plasma
                  derivatives within 3 months prior to Visit 1 or planned during the full length of
                  the study,

               5. known HIV infection or HIV-related disease;

          4. History of Guillain-Barré syndrome;

          5. Bleeding diathesis;

          6. Surgery planned during the study period;

          7. Receipt of another investigational agent within 90 days, or before completion of the
             safety follow-up period in another study, whichever is longer, prior to enrollment and
             unwilling to refuse participation in another clinical study through the end of the
             study;

          8. Receipt of another vaccine within 2 weeks (for inactivated vaccines) or 4 weeks (for
             live vaccines) prior to Visit 1;

          9. Laboratory-confirmed influenza disease within 6 months prior to Visit 1;

         10. For subjects aged 3 to 8 years old, ever received two doses of an influenza vaccine in
             one influenza season;

         11. Receipt of an influenza vaccine within 6 months prior to Visit 1;

         12. Experienced a temperature 38.0°C [100.4°F]) and/or any acute illness within 3 days
             prior to Visit 1;

         13. Pregnant or nursing mother;

         14. Female of childbearing potential who is sexually active and has not used acceptable
             birth control measures for at least 2 months prior to study entry and who does not
             plan to use acceptable birth control measures during the 3 weeks following vaccination
             or refuses to have a urine pregnancy test prior to enrollment. Oral, injected,
             inserted or implanted hormonal contraceptive, diaphragm or condom with spermicidal
             agent or intrauterine device are considered acceptable forms of birth control;

         15. Children of research staff or those living with research staff directly involved with
             the clinical study. Research staff are individuals with direct study subject contact,
             indirect contact with study subjects, or study site personnel who have access to any
             study documents containing subject information. This would include receptionists,
             persons scheduling appointments or making screening calls, regulatory specialists,
             laboratory technicians, etc.;

         16. Any condition, which in the opinion of the Investigator, might interfere with the
             evaluation of the study objectives.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Vaccines</last_name>
    <role>Study Chair</role>
    <affiliation>Novartis Vaccines</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site 09</name>
      <address>
        <city>Fayetteville</city>
        <state>Arkansas</state>
        <zip>72703</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 10</name>
      <address>
        <city>Downey</city>
        <state>California</state>
        <zip>90241</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 02</name>
      <address>
        <city>Bardstown</city>
        <state>Kentucky</state>
        <zip>40004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 14</name>
      <address>
        <city>Metairie</city>
        <state>Louisiana</state>
        <zip>70006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 01</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 11</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 04</name>
      <address>
        <city>Edison</city>
        <state>New Jersey</state>
        <zip>08817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 05</name>
      <address>
        <city>Endwell</city>
        <state>New York</state>
        <zip>13760</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 16</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76135</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 13</name>
      <address>
        <city>San Angelo</city>
        <state>Texas</state>
        <zip>76904</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 12</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 08</name>
      <address>
        <city>Bountiful</city>
        <state>Utah</state>
        <zip>84010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 07</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 03</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 06</name>
      <address>
        <city>Burke</city>
        <state>Virginia</state>
        <zip>22105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 15</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 44:Spec. Pediatric Dispensary</name>
      <address>
        <city>Dakovo</city>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 83</name>
      <address>
        <city>Ljudevita Gaja 2, Djakovo</city>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 43: Spec. Pediatric Dispensary</name>
      <address>
        <city>Sisak</city>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 27:Institute of Public Health</name>
      <address>
        <city>Zagreb</city>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 29: Institute of Public Health</name>
      <address>
        <city>Zagreb</city>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 40:Spec. Pediatric Dispensary</name>
      <address>
        <city>Zagreb</city>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 49: Spec. Pediatric Dispensary</name>
      <address>
        <city>Zagreb</city>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 50: Spec. Pediatric Dispensary</name>
      <address>
        <city>Zagreb</city>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 86: Spec. Pediatric Dispensary</name>
      <address>
        <city>Zagreb</city>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 70: Espoon rokotetutkimusklinikka</name>
      <address>
        <city>Heikintori</city>
        <state>Espoo</state>
        <zip>02100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 79: Kokkola Vaccine Research Clinic</name>
      <address>
        <city>Rantakatu 7</city>
        <state>Kokkola</state>
        <zip>67100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 78: Kuopio Vaccine Research Clinic</name>
      <address>
        <city>Microkatu 1,Osa/Section A, 3rd floor PL1188</city>
        <state>Kuopio</state>
        <zip>70211</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 71: Etelä-Helsingin rokotetutkimusklinikka</name>
      <address>
        <city>Helsinki</city>
        <zip>00100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 72: Itä-Helsingin rokotetutkimusklinikka</name>
      <address>
        <city>Helsinki</city>
        <zip>00930</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 76: Järvenpään rokotetutkimusklinikka</name>
      <address>
        <city>Järvenpää</city>
        <zip>04400</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 77: Kotkan rokotetutkimusklinikka</name>
      <address>
        <city>Kotka</city>
        <zip>48600</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 67: Lahden rokotetutkimusklinikka</name>
      <address>
        <city>Lahti</city>
        <zip>15140</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 75: Oulun rokotetutkimusklinikka</name>
      <address>
        <city>Oulu</city>
        <zip>90100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 68: Porin rokotetutkimusklinikka</name>
      <address>
        <city>Pori</city>
        <zip>28120</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 66: Tampereen rokotetutkimusklinikka</name>
      <address>
        <city>Tampere</city>
        <zip>33100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 69: Turun rokotetutkimusklinikka</name>
      <address>
        <city>Turku</city>
        <zip>20520</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 73: Itä-Vantaan rokotetutkimusklinikka</name>
      <address>
        <city>Vantaa</city>
        <zip>01300</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 74: Länsi-Vantaan rokotetutkimusklinikka</name>
      <address>
        <city>Vantaa</city>
        <zip>01600</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 57: Házi Gyermekorvosi Rendelő</name>
      <address>
        <city>Budapest</city>
        <zip>1042</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 53: Heim Pál Gyermekkórház</name>
      <address>
        <city>Budapest</city>
        <zip>1089</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 52: Ferencvárosi Gyermekorvos Kft.</name>
      <address>
        <city>Budapest</city>
        <zip>1097</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 56: Házi Gyermekorvosi Rendelő</name>
      <address>
        <city>Budapest</city>
        <zip>1136</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 54: Házi Gyermekorvosi Rendelő</name>
      <address>
        <city>Budapest</city>
        <zip>1173</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 51: 5053. számú Gyermekorvosi Rendelő</name>
      <address>
        <city>Miskolc</city>
        <zip>3534</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 55: Revamed kft.</name>
      <address>
        <city>Nyíregyháza</city>
        <zip>4481</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 59: Vas Megyei Markusovszky Lajos, Általános, Rehabilitációs és Gyógyfürdő Kórház, Egyetemi Oktató Kórház</name>
      <address>
        <city>Szombathely</city>
        <zip>9700</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 42: Dipartimento di Medicina Clinica e Sperimentale - Sezione di Igiene e Medicina Preventiva</name>
      <address>
        <city>Ferrara</city>
        <zip>44100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 47: Dipartimento Scienze della Salute, Sezione di Igiene e Medicina Preventiva, Univesità di Genova</name>
      <address>
        <city>Genova</city>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 41: Ospedale Maggiore della Carità-Clinica Pediatrica</name>
      <address>
        <city>Novara</city>
        <zip>28100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 46: USL 2 Perugia, Distretto del perugino, Centro di Salute n. 4 (Madonna Alta) e n. 6 (Ellera di Corciano del distretto del perugino)</name>
      <address>
        <city>Perugia</city>
        <zip>06070</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 45: AUSL 7</name>
      <address>
        <city>Ragusa</city>
        <zip>97100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 35</name>
      <address>
        <city>Kaunas</city>
        <zip>48259</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 36</name>
      <address>
        <city>Vilnius</city>
        <zip>01117</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 32</name>
      <address>
        <city>Vilnius</city>
        <zip>02169</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 34</name>
      <address>
        <city>Vilnius</city>
        <zip>04318</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 31</name>
      <address>
        <city>Vilnius</city>
        <zip>10207</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 33</name>
      <address>
        <city>Vilnius</city>
        <zip>11200</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 25</name>
      <address>
        <city>Campulung Muscel</city>
        <state>Arges</state>
        <zip>115100</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 21</name>
      <address>
        <city>Craiova</city>
        <state>Dolj</state>
        <zip>200642</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Croatia</country>
    <country>Finland</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Lithuania</country>
    <country>Romania</country>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Vesikari T, Block SL, Guerra F, Lattanzi M, Holmes S, Izu A, Gaitatzis N, Hilbert AK, Groth N. Immunogenicity, safety and reactogenicity of a mammalian cell-culture-derived influenza vaccine in healthy children and adolescents three to seventeen years of age. Pediatr Infect Dis J. 2012 May;31(5):494-500. doi: 10.1097/INF.0b013e31824bb179.</citation>
    <PMID>22301476</PMID>
  </results_reference>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 21, 2008</study_first_submitted>
  <study_first_submitted_qc>March 21, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 27, 2008</study_first_posted>
  <results_first_submitted>November 21, 2012</results_first_submitted>
  <results_first_submitted_qc>January 15, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 16, 2013</results_first_posted>
  <disposition_first_submitted>March 25, 2011</disposition_first_submitted>
  <disposition_first_submitted_qc>March 25, 2011</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">April 4, 2011</disposition_first_posted>
  <last_update_submitted>October 20, 2015</last_update_submitted>
  <last_update_submitted_qc>October 20, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 23, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Influenza</keyword>
  <keyword>Flu</keyword>
  <keyword>Cell Culture-Derived</keyword>
  <keyword>Egg-Derived</keyword>
  <keyword>Healthy Children</keyword>
  <keyword>Healthy Adolescents</keyword>
  <keyword>Safety</keyword>
  <keyword>Immunogenicity</keyword>
  <keyword>Trivalent</keyword>
  <keyword>Inactivated</keyword>
  <keyword>Vaccination</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were enrolled from 14 sites in Finland, 16 in the US, 9 in Croatia, 5 in Italy, 6 in Lithuania, 2 in Romania, 8 in Hungary.</recruitment_details>
      <pre_assignment_details>All subjects enrolled were included in the trial.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Cohort 1+2 cTIV (9-17 Years)</title>
          <description>All subjects aged 9-17 years received one 0.5 mL injection, of Cell Culture-derived trivalent influenza vaccine.</description>
        </group>
        <group group_id="P2">
          <title>Cohort 1+2 eTIV (9-17 Years)</title>
          <description>All subjects aged 9-17 years received one 0.5 mL injection, of egg -derived trivalent influenza vaccine.</description>
        </group>
        <group group_id="P3">
          <title>Cohort 3 cTIV (3-8 Years)</title>
          <description>All subjects aged 3-8 years received two 0.5 mL injections, administered four weeks apart, of Cell Culture-derived trivalent influenza vaccine.</description>
        </group>
        <group group_id="P4">
          <title>Cohort 3 eTIV (3-8 Years)</title>
          <description>All subjects aged 3-8 years received two 0.5 mL injections, administered four weeks apart of egg-derived trivalent influenza vaccine.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="656"/>
                <participants group_id="P2" count="318"/>
                <participants group_id="P3" count="1608"/>
                <participants group_id="P4" count="1022"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="643"/>
                <participants group_id="P2" count="312"/>
                <participants group_id="P3" count="1457"/>
                <participants group_id="P4" count="919"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="151"/>
                <participants group_id="P4" count="103"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="19"/>
                <participants group_id="P4" count="21"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="124"/>
                <participants group_id="P4" count="75"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Inappropriate enrollment</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unable to classify</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Cohort 1+2 cTIV (9-17 Years)</title>
          <description>All subjects aged 9-17 years received one 0.5 mL injection, of Cell Culture-derived trivalent influenza vaccine.</description>
        </group>
        <group group_id="B2">
          <title>Cohort 1+2 eTIV (9-17 Years)</title>
          <description>All subjects aged 9-17 years received one 0.5 mL injection, of egg-derived trivalent influenza vaccine.</description>
        </group>
        <group group_id="B3">
          <title>Cohort 3 cTIV (3-8 Years)</title>
          <description>All subjects aged 3-8 years received two 0.5 mL injections, administered four weeks apart, of Cell Culture-derived trivalent influenza vaccine.</description>
        </group>
        <group group_id="B4">
          <title>Cohort 3 eTIV (3-8 Years)</title>
          <description>All subjects aged 3-8 years received two 0.5 mL injections, administered four weeks apart of egg-derived trivalent influenza vaccine.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="656"/>
            <count group_id="B2" value="318"/>
            <count group_id="B3" value="1608"/>
            <count group_id="B4" value="1022"/>
            <count group_id="B5" value="3604"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12.6" spread="2.6"/>
                    <measurement group_id="B2" value="12.6" spread="2.5"/>
                    <measurement group_id="B3" value="5.5" spread="1.7"/>
                    <measurement group_id="B4" value="5.4" spread="1.7"/>
                    <measurement group_id="B5" value="7.4" spread="3.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="304"/>
                    <measurement group_id="B2" value="154"/>
                    <measurement group_id="B3" value="795"/>
                    <measurement group_id="B4" value="494"/>
                    <measurement group_id="B5" value="1747"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="352"/>
                    <measurement group_id="B2" value="164"/>
                    <measurement group_id="B3" value="813"/>
                    <measurement group_id="B4" value="528"/>
                    <measurement group_id="B5" value="1857"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Titers of the Cell Culture-derived Vaccine Compared With the Egg-derived Vaccine in 3 to 8 Year-old Children</title>
        <description>To demonstrate non-inferiority of the post vaccination hemagglutination inhibition (HI) geometric mean titer (GMT) of the cell culture-derived influenza (cTIV) vaccine to the corresponding GMT of the egg-derived (eTIV) influenza vaccine, for all three strains, after two injections administered four weeks apart to a subset of children 3 to 8 years of age.
GMTs were evaluated using two assays, HI egg derived antigen assay and HI cell derived antigen assay.</description>
        <time_frame>Day 50 post vaccination</time_frame>
        <population>The analysis was performed on the per-protocol dataset</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 3 cTIV (3-8 Years)</title>
            <description>All subjects aged 3-8 years received two 0.5 mL injections, administered four weeks apart, of Cell Culture-derived trivalent influenza vaccine.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 3 eTIV (3-8 Years)</title>
            <description>All subjects aged 3-8 years received two 0.5 mL injections, administered four weeks apart of egg - derived trivalent influenza vaccine.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers of the Cell Culture-derived Vaccine Compared With the Egg-derived Vaccine in 3 to 8 Year-old Children</title>
          <description>To demonstrate non-inferiority of the post vaccination hemagglutination inhibition (HI) geometric mean titer (GMT) of the cell culture-derived influenza (cTIV) vaccine to the corresponding GMT of the egg-derived (eTIV) influenza vaccine, for all three strains, after two injections administered four weeks apart to a subset of children 3 to 8 years of age.
GMTs were evaluated using two assays, HI egg derived antigen assay and HI cell derived antigen assay.</description>
          <population>The analysis was performed on the per-protocol dataset</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="524"/>
                <count group_id="O2" value="513"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1 (egg derived antigen assay)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="407" lower_limit="358" upper_limit="462"/>
                    <measurement group_id="O2" value="477" lower_limit="419" upper_limit="542"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2 (egg derived antigen assay)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="768" lower_limit="666" upper_limit="885"/>
                    <measurement group_id="O2" value="1293" lower_limit="1121" upper_limit="1491"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B (egg derived antigen assay)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25" lower_limit="21" upper_limit="29"/>
                    <measurement group_id="O2" value="44" lower_limit="38" upper_limit="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H1N1 (cell derived antigen assay) (N=522,513)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="563" lower_limit="501" upper_limit="634"/>
                    <measurement group_id="O2" value="610" lower_limit="542" upper_limit="686"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2 (cell derived antigen assay) (N=522,513)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="858" lower_limit="744" upper_limit="990"/>
                    <measurement group_id="O2" value="1329" lower_limit="1152" upper_limit="1533"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B (cell derived antigen assay) (N=522,513)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53" lower_limit="46" upper_limit="62"/>
                    <measurement group_id="O2" value="62" lower_limit="53" upper_limit="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Non-inferiority of cTIV to eTIV against A/H1N1 influenza strain as measured by HI egg-derived antigen assay</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Cell derived vaccine was considered non-inferior to egg-derived vaccine in post vaccination HI GMTs if, for all three influenza strains, the lower limit of the two-sided 95% confidence interval (CI) for day 50 ratio of GMTs (cTIV/eTIV) was &gt;0.667.</non_inferiority_desc>
            <param_type>Ratio of GMTs</param_type>
            <param_value>0.85</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.72</ci_lower_limit>
            <ci_upper_limit>1.01</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Non-inferiority of cTIV to eTIV against A/H3N2 influenza strain as measured by HI egg-derived antigen assay.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Cell derived vaccine (cTIV ) was considered non-inferior to egg-derived vaccine (eTIV) in postvaccination HI GMTs if, for all three influenza strains, the lower limit of the two-sided 95% confidence interval (CI) for day 50 ratio of GMTs(cTIV/eTIV) was &gt;0.667.</non_inferiority_desc>
            <param_type>Ratio of GMTs</param_type>
            <param_value>0.59</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.49</ci_lower_limit>
            <ci_upper_limit>0.72</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Non-inferiority of cTIV to eTIV against influenza B strain as measured by HI egg-derived antigen assay.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Cell derived vaccine (cTIV ) was considered non-inferior to egg-derived vaccine (eTIV)in post vaccination HI GMTs if, for all three influenza strains, the lower limit of the two-sided 95% confidence interval (CI) for day 50 ratio of GMTs (cTIV/eTIV) was &gt;0.667.</non_inferiority_desc>
            <param_type>Ratio of GMTs</param_type>
            <param_value>0.56</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.46</ci_lower_limit>
            <ci_upper_limit>0.68</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Non-inferiority of cTIV to eTIV against A/H1N1 influenza strain as measured by HI cell-derived antigen assay.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Cell derived vaccine (cTIV) was considered non-inferior to egg-derived vaccine (eTIV) in post vaccination HI GMTs if, for all three influenza strains, the lower limit of the two-sided 95% confidence interval (CI) for day 50 ratio of GMTs (cTIV/eTIV) was &gt;0.667.</non_inferiority_desc>
            <param_type>Ratio of GMTs</param_type>
            <param_value>0.92</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.79</ci_lower_limit>
            <ci_upper_limit>1.08</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Non-inferiority of cTIV to eTIV against A/H3N2 influenza strain as measured by HI cell-derived antigen assay.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Cell derived vaccine (cTIV) was considered non-inferior to egg-derived vaccine (eTIV)in post vaccination HI GMTs if, for all three influenza strains, the lower limit of the two-sided 95% confidence interval (CI) for day 50 ratio of GMTs (cTIV/eTIV) was &gt;0.667.</non_inferiority_desc>
            <param_type>Ratio of GMTs</param_type>
            <param_value>0.65</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.54</ci_lower_limit>
            <ci_upper_limit>0.78</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Non-inferiority of cTIV to eTIV against B influenza strain as measured by HI cell-derived antigen assay.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Cell derived vaccine (cTIV) was considered non-inferior to egg-derived vaccine (eTIV)in post vaccination HI GMTs if, for all three influenza strains, the lower limit of the two-sided 95% confidence interval (CI) for day 50 ratio of GMTs (cTIV/eTIV)was &gt;0.667.</non_inferiority_desc>
            <param_type>Ratio of GMTs</param_type>
            <param_value>0.87</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.71</ci_lower_limit>
            <ci_upper_limit>1.06</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentages of Subjects Who Attained Seroconversion or Significant Increase in Antibody Titers in the Cell Culture-derived Vaccine Compared With the Egg-derived Vaccine in 3 to 8 Year-old Children</title>
        <description>To demonstrate non-inferiority of the cell culture-derived influenza (cTIV) vaccine to the egg-derived (eTIV) influenza vaccine in the percentage of subjects achieving seroconversion or significant increase in antibody titer post vaccination, for all three strains, after two injections administered four weeks apart in children 3 to 8 years of age.
Seroconversion rate was evaluated using two assays- HI egg derived antigen assay and HI cell derived antigen assay.</description>
        <time_frame>Day 50 post vaccination</time_frame>
        <population>The analysis was performed on the per-protocol dataset</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 3 cTIV (3-8 Years)</title>
            <description>All subjects aged 3-8 years received two 0.5 mL injections, administered four weeks apart, of Cell Culture-derived trivalent influenza vaccine.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 3 eTIV (3-8 Years)</title>
            <description>All subjects aged 3-8 years received two 0.5 mL injections, administered four weeks apart of egg-derived trivalent influenza vaccine.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages of Subjects Who Attained Seroconversion or Significant Increase in Antibody Titers in the Cell Culture-derived Vaccine Compared With the Egg-derived Vaccine in 3 to 8 Year-old Children</title>
          <description>To demonstrate non-inferiority of the cell culture-derived influenza (cTIV) vaccine to the egg-derived (eTIV) influenza vaccine in the percentage of subjects achieving seroconversion or significant increase in antibody titer post vaccination, for all three strains, after two injections administered four weeks apart in children 3 to 8 years of age.
Seroconversion rate was evaluated using two assays- HI egg derived antigen assay and HI cell derived antigen assay.</description>
          <population>The analysis was performed on the per-protocol dataset</population>
          <units>Percentages of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="524"/>
                <count group_id="O2" value="513"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1 (egg derived antigen assay)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94" lower_limit="92" upper_limit="96"/>
                    <measurement group_id="O2" value="96" lower_limit="94" upper_limit="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2 (egg derived antigen assay)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77" lower_limit="73" upper_limit="81"/>
                    <measurement group_id="O2" value="86" lower_limit="82" upper_limit="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B (egg derived antigen assay)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38" lower_limit="34" upper_limit="42"/>
                    <measurement group_id="O2" value="53" lower_limit="49" upper_limit="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H1N1 (cell derived antigen assay) (N=522,513)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96" lower_limit="93" upper_limit="97"/>
                    <measurement group_id="O2" value="96" lower_limit="94" upper_limit="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2 (cell derived antigen assay) (N=522,513)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80" lower_limit="76" upper_limit="83"/>
                    <measurement group_id="O2" value="85" lower_limit="82" upper_limit="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B (cell derived antigen assay) (N=522,513)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58" lower_limit="54" upper_limit="63"/>
                    <measurement group_id="O2" value="58" lower_limit="54" upper_limit="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Non-inferiority of cTIV to eTIV against A/H1N1 influenza strain as measured by HI egg-derived antigen assay.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>cTIV was considered non-inferior to eTIV in terms of the percentages of subjects achieving seroconversion or significant increase in antibody titer at day 50 if for all three strains, the lower limit of the two-sided 95% CI around the differences in the percentages of subjects achieving seroconversion and significant increase (cTIV minus eTIV) was &gt;-10%.</non_inferiority_desc>
            <param_type>Difference in % (cTIV minus eTIV)</param_type>
            <param_value>-1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4</ci_lower_limit>
            <ci_upper_limit>1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Non-inferiority of cTIV to eTIV against A/H3N2 influenza strain as measured by HI egg-derived antigen assay.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>cTIV was considered non-inferior to eTIV in terms of the percentages of subjects achieving seroconversion or significant increase in antibody titer at day 50 if for all three strains, the lower limit of the two-sided 95% CI around the differences in the percentages of subjects achieving seroconversion and significant increase (cTIV minus eTIV) was &gt;-10%.</non_inferiority_desc>
            <param_type>Difference % (cTIV - eTIV)</param_type>
            <param_value>-9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-13</ci_lower_limit>
            <ci_upper_limit>-4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Non-inferiority of cTIV to eTIV against B influenza strain as measured by HI egg-derived antigen assay.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>cTIV was considered non-inferior to eTIV in terms of the percentages of subjects achieving seroconversion or significant increase in antibody titer at day 50 if for all three strains, the lower limit of the two-sided 95% CI around the differences in the percentages of subjects achieving seroconversion and significant increase (cTIV minus eTIV) was &gt;-10%.</non_inferiority_desc>
            <param_type>Difference % (cTIV minus eTIV)</param_type>
            <param_value>-15</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-21</ci_lower_limit>
            <ci_upper_limit>-9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Non-inferiority of cTIV to eTIV against A/H1N1 influenza strain as measured by HI cell-derived antigen assay.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>cTIV was considered non-inferior to eTIV in terms of the percentages of subjects achieving seroconversion or significant increase in antibody titer at day 50 if for all three strains, the lower limit of the two-sided 95% CI around the differences in the percentages of subjects achieving seroconversion and significant increase (cTIV minus eTIV) was &gt;-10%</non_inferiority_desc>
            <param_type>Difference % (cTIV minus eTIV)</param_type>
            <param_value>-1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3</ci_lower_limit>
            <ci_upper_limit>2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Non-inferiority of cTIV to eTIV against A/H3N2 influenza strain as measured by HI cell-derived antigen assay.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>cTIV was considered non-inferior to eTIV in terms of the percentages of subjects achieving seroconversion or significant increase in antibody titer at day 50 if for all three strains, the lower limit of the two-sided 95% CI around the differences in the percentages of subjects achieving seroconversion and significant increase (cTIV minus eTIV) was &gt;-10%.</non_inferiority_desc>
            <param_type>Difference % (cTIV minus eTIV)</param_type>
            <param_value>-5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.5</ci_lower_limit>
            <ci_upper_limit>0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Non-inferiority of cTIV to eTIV against B influenza strain as measured by HI cell-derived antigen assay.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>cTIV was considered non-inferior to eTIV in terms of the percentages of subjects achieving seroconversion or significant increase in antibody titer at day 50 if for all three strains, the lower limit of the two-sided 95% CI around the differences in the percentages of subjects achieving seroconversion and significant increase (cTIV minus eTIV) was &gt;-10%.</non_inferiority_desc>
            <param_type>Difference % (cTIV minus eTIV)</param_type>
            <param_value>0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6</ci_lower_limit>
            <ci_upper_limit>6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Titers After 1 Dose of the Cell Culture-derived or the Egg-derived Influenza Vaccine in 9 to 17 Year-old Children and Adolescents</title>
        <description>To evaluate immunogenicity in terms of Geometric Mean Titers (GMTs) in children 9 to 17 years of age after one injection of either cTIV vaccine or eTIV.
GMTs were evaluated using two assays, HI egg derived antigen assay and HI cell derived antigen assay.</description>
        <time_frame>Day 29 post vaccination</time_frame>
        <population>The analysis was performed on the per-protocol dataset.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1 cTIV (9-17 Years)</title>
            <description>All subjects aged 9-17 years received one 0.5 mL injection, of Cell Culture-derived trivalent influenza vaccine</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1 eTIV (9-17 Years)</title>
            <description>All subjects aged 9-17 years received one 0.5 mL injection, of egg-derived trivalent influenza vaccine.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers After 1 Dose of the Cell Culture-derived or the Egg-derived Influenza Vaccine in 9 to 17 Year-old Children and Adolescents</title>
          <description>To evaluate immunogenicity in terms of Geometric Mean Titers (GMTs) in children 9 to 17 years of age after one injection of either cTIV vaccine or eTIV.
GMTs were evaluated using two assays, HI egg derived antigen assay and HI cell derived antigen assay.</description>
          <population>The analysis was performed on the per-protocol dataset.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="142"/>
                <count group_id="O2" value="144"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (A/H1N1) egg derived antigen assay</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55" lower_limit="42" upper_limit="72"/>
                    <measurement group_id="O2" value="78" lower_limit="60" upper_limit="101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29 (A/H1N1) egg derived antigen assay</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="879" lower_limit="728" upper_limit="1062"/>
                    <measurement group_id="O2" value="1107" lower_limit="918" upper_limit="1334"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline (A/H3N2) egg derived antigen assay</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="121" lower_limit="94" upper_limit="155"/>
                    <measurement group_id="O2" value="151" lower_limit="118" upper_limit="193"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29 (A/H3N2) egg derived antigen assay</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="706" lower_limit="607" upper_limit="821"/>
                    <measurement group_id="O2" value="1857" lower_limit="1598" upper_limit="2157"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline (B) Egg derived antigen assay</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.65" lower_limit="8.2" upper_limit="11"/>
                    <measurement group_id="O2" value="9.92" lower_limit="8.45" upper_limit="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29 (B) egg derived antigen assay</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58" lower_limit="48" upper_limit="71"/>
                    <measurement group_id="O2" value="105" lower_limit="86" upper_limit="129"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline(A/H1N1)Cell derived assay</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70" lower_limit="53" upper_limit="92"/>
                    <measurement group_id="O2" value="90" lower_limit="69" upper_limit="119"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29 (A/H1N1) cell derived antigen assay</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1076" lower_limit="886" upper_limit="1307"/>
                    <measurement group_id="O2" value="1296" lower_limit="1069" upper_limit="1571"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline(A/H3N2)cell derived assay(N=141,144)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="125" lower_limit="98" upper_limit="158"/>
                    <measurement group_id="O2" value="144" lower_limit="114" upper_limit="182"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29 (A/H3N2) cell derived antigen assay</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="676" lower_limit="585" upper_limit="783"/>
                    <measurement group_id="O2" value="1651" lower_limit="1429" upper_limit="1908"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline(B)cell derived assay(N=141,144)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22" lower_limit="18" upper_limit="27"/>
                    <measurement group_id="O2" value="25" lower_limit="21" upper_limit="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29 (B) cell derived antigen assay</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="136" lower_limit="113" upper_limit="163"/>
                    <measurement group_id="O2" value="186" lower_limit="155" upper_limit="222"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Ratio After 1 Dose of the Cell Culture-derived or the Egg-derived Influenza Vaccine in 9 to 17 Year-old Children and Adolescents.</title>
        <description>Immunogenicity was evaluated in terms of Geometric Mean Ratio (GMRs) in 9 to 17 year-old children and adolescents after one injection of either cTIV vaccine or eTIV.
The criterion is met according to European (CHMP) guideline if the mean geometric increase GMR (day29/day1) in HI antibody titer is &gt;2.5.</description>
        <time_frame>Day 29 post vaccination</time_frame>
        <population>The analysis was performed on the per-protocol dataset.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1 cTIV (9-17 Years)</title>
            <description>All subjects aged 9-17 years received one 0.5 mL injection, of Cell Culture-derived trivalent influenza vaccine.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1 eTIV (9-17 Years)</title>
            <description>All subjects aged 9-17 years received one 0.5 mL injection, of egg-derived trivalent influenza vaccine.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Ratio After 1 Dose of the Cell Culture-derived or the Egg-derived Influenza Vaccine in 9 to 17 Year-old Children and Adolescents.</title>
          <description>Immunogenicity was evaluated in terms of Geometric Mean Ratio (GMRs) in 9 to 17 year-old children and adolescents after one injection of either cTIV vaccine or eTIV.
The criterion is met according to European (CHMP) guideline if the mean geometric increase GMR (day29/day1) in HI antibody titer is &gt;2.5.</description>
          <population>The analysis was performed on the per-protocol dataset.</population>
          <units>Ratio</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="142"/>
                <count group_id="O2" value="144"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 29 (A/H1N1)egg derived antigen assay</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16" lower_limit="12" upper_limit="21"/>
                    <measurement group_id="O2" value="14" lower_limit="11" upper_limit="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29 (A/H3N2) egg derived antigen assay</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.84" lower_limit="4.43" upper_limit="7.7"/>
                    <measurement group_id="O2" value="12" lower_limit="9.33" upper_limit="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29 (B) egg derived antigen assay</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.03" lower_limit="4.77" upper_limit="7.62"/>
                    <measurement group_id="O2" value="11" lower_limit="8.43" upper_limit="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day29(A/H1N1)cell derived antigen assay(N=141,144)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15" lower_limit="12" upper_limit="21"/>
                    <measurement group_id="O2" value="14" lower_limit="11" upper_limit="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day29(A/H3N2)cell derived antigen assay(N=141,144)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.45" lower_limit="4.21" upper_limit="7.06"/>
                    <measurement group_id="O2" value="11" lower_limit="8.87" upper_limit="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day29(B) cell derived antigen assay(N=141,144)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.15" lower_limit="4.96" upper_limit="7.63"/>
                    <measurement group_id="O2" value="7.37" lower_limit="5.96" upper_limit="9.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentages of Subjects Who Achieved HI Titers ≥40 After 1 Dose of the Cell Culture-derived Vaccine or the Egg-derived Influenza Vaccine in 9 to 17 Year-old Children and Adolescents</title>
        <description>To evaluate immunogenicity in terms of percentage of 9 to 17 year-old children and adolescents achieving HI titers ≥40, after one injection of either the cTIV vaccine or the eTIV vaccine.
This criterion is met according to European (CHMP) guideline if the percentage of subjects achieving HI titers ≥40 is &gt;70% and according to the US (CBER) guideline is met if the lower bound of the two sided 95%CI for percentage of subjects achieving HI titers ≥40 is ≥70%.</description>
        <time_frame>Day 29 post vaccination</time_frame>
        <population>The analysis was performed on the per-protocol dataset.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1 cTIV (9-17 Years)</title>
            <description>All subjects aged 9-17 years received one 0.5 mL injection, of Cell Culture-derived trivalent influenza vaccine.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1 eTIV (9-17 Years)</title>
            <description>All subjects aged 9-17 years received one 0.5 mL injection, of egg-derived trivalent influenza vaccine.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages of Subjects Who Achieved HI Titers ≥40 After 1 Dose of the Cell Culture-derived Vaccine or the Egg-derived Influenza Vaccine in 9 to 17 Year-old Children and Adolescents</title>
          <description>To evaluate immunogenicity in terms of percentage of 9 to 17 year-old children and adolescents achieving HI titers ≥40, after one injection of either the cTIV vaccine or the eTIV vaccine.
This criterion is met according to European (CHMP) guideline if the percentage of subjects achieving HI titers ≥40 is &gt;70% and according to the US (CBER) guideline is met if the lower bound of the two sided 95%CI for percentage of subjects achieving HI titers ≥40 is ≥70%.</description>
          <population>The analysis was performed on the per-protocol dataset.</population>
          <units>Percentages of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="142"/>
                <count group_id="O2" value="144"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Prevaccination (A/H1N1)egg derived antigen assay</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65" lower_limit="57" upper_limit="73"/>
                    <measurement group_id="O2" value="75" lower_limit="67" upper_limit="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29 (A/H1N1) egg derived antigen assay</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99" lower_limit="96" upper_limit="100"/>
                    <measurement group_id="O2" value="99" lower_limit="95" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Prevaccination (A/H3N2) egg derived antigen assay</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82" lower_limit="74" upper_limit="88"/>
                    <measurement group_id="O2" value="86" lower_limit="79" upper_limit="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29 (A/H3N2) egg derived antigen assay</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="97" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="97" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Prevaccination(B)egg derived antigen assay</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17" lower_limit="11" upper_limit="24"/>
                    <measurement group_id="O2" value="13" lower_limit="8" upper_limit="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29 (B) egg derived antigen assay</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75" lower_limit="67" upper_limit="82"/>
                    <measurement group_id="O2" value="84" lower_limit="77" upper_limit="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Prevaccination (H1N1)cell derived assay(N=141,144)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67" lower_limit="59" upper_limit="75"/>
                    <measurement group_id="O2" value="78" lower_limit="71" upper_limit="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29 (A/H1N1)cell derived antigen assay</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99" lower_limit="96" upper_limit="100"/>
                    <measurement group_id="O2" value="98" lower_limit="94" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Prevaccination (H3N2)cell derived assay(N=141,144)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83" lower_limit="76" upper_limit="89"/>
                    <measurement group_id="O2" value="86" lower_limit="79" upper_limit="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29 (A/H3N2) cell derived antigen assay</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="97" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="97" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Prevaccination (B) cell derived assay(N=141,144)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40" lower_limit="32" upper_limit="49"/>
                    <measurement group_id="O2" value="47" lower_limit="38" upper_limit="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29 (B) cell derived antigen assay</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95" lower_limit="90" upper_limit="98"/>
                    <measurement group_id="O2" value="94" lower_limit="89" upper_limit="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentages of Subjects Who Attained Seroconversion or Significant Increase After 1 Dose of the Cell Culture-derived Vaccine or the Egg-derived Influenza Vaccine in 9 to 17 Year-old Children and Adolescents</title>
        <description>Seroconversion or significant increase as per CHMP criteria is defined as percentage of subjects with a pre vaccination HI titer &lt;10 to a post vaccination titer ≥40 or a pre vaccination HI titer ≥10 and a ≥4-fold increase in post vaccination HI antibody titer. According to the CHMP criteria, the percentage of subjects achieving seroconversion or significant increase should be &gt;40%.
According to the CBER criteria, the lower bound of the two-sided 95% CI for the percentage of subjects achieving seroconversion/significant increase should be ≥40%.</description>
        <time_frame>Day 29 post vaccination</time_frame>
        <population>The analysis was performed on the per-protocol dataset.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1 cTIV (9-17 Years)</title>
            <description>All subjects aged 9-17 years received one 0.5 mL injection, of Cell Culture-derived trivalent influenza vaccine.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1 eTIV (9-17 Years)</title>
            <description>All subjects aged 9-17 years received one 0.5 mL injection, of egg-derived trivalent influenza vaccine.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages of Subjects Who Attained Seroconversion or Significant Increase After 1 Dose of the Cell Culture-derived Vaccine or the Egg-derived Influenza Vaccine in 9 to 17 Year-old Children and Adolescents</title>
          <description>Seroconversion or significant increase as per CHMP criteria is defined as percentage of subjects with a pre vaccination HI titer &lt;10 to a post vaccination titer ≥40 or a pre vaccination HI titer ≥10 and a ≥4-fold increase in post vaccination HI antibody titer. According to the CHMP criteria, the percentage of subjects achieving seroconversion or significant increase should be &gt;40%.
According to the CBER criteria, the lower bound of the two-sided 95% CI for the percentage of subjects achieving seroconversion/significant increase should be ≥40%.</description>
          <population>The analysis was performed on the per-protocol dataset.</population>
          <units>Percentages of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="142"/>
                <count group_id="O2" value="144"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 29 (A/H1N1) egg derived antigen assay</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77" lower_limit="70" upper_limit="84"/>
                    <measurement group_id="O2" value="77" lower_limit="69" upper_limit="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29 (A/H3N2) egg derived antigen assay</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56" lower_limit="48" upper_limit="65"/>
                    <measurement group_id="O2" value="77" lower_limit="69" upper_limit="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29 (B) egg derived antigen assay</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56" lower_limit="48" upper_limit="65"/>
                    <measurement group_id="O2" value="71" lower_limit="63" upper_limit="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day29(A/H1N1)cell derived antigen assay(N=141,144)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74" lower_limit="66" upper_limit="81"/>
                    <measurement group_id="O2" value="74" lower_limit="66" upper_limit="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day29(A/H3N2)cell derived antigen assay(N=141,144)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52" lower_limit="44" upper_limit="61"/>
                    <measurement group_id="O2" value="78" lower_limit="70" upper_limit="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day29(B)cell derived antigen assay (N=141,144)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63" lower_limit="55" upper_limit="71"/>
                    <measurement group_id="O2" value="69" lower_limit="61" upper_limit="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Titers After Two Doses of the Cell Derived or the Egg Derived Vaccine in 3 to 8 Year-old Children</title>
        <description>To evaluate immunogenicity in terms of Geometric Mean Titers (GMTs) in children 3 to 8 years of age after two doses of either cTIV vaccine or eTIV,administered 4 weeks apart.</description>
        <time_frame>Day 29 and Day 50 post vaccination</time_frame>
        <population>The analysis was performed on the per-protocol dataset.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 3 cTIV (3-8 Years)</title>
            <description>All subjects aged 3-8 years received two 0.5 mL injections, administered four weeks apart, of Cell Culture-derived trivalent influenza vaccine.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 3 eTIV (3-8 Years)</title>
            <description>All subjects aged 3-8 years received two 0.5 mL injections, administered four weeks apart of egg-derived trivalent influenza vaccine.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers After Two Doses of the Cell Derived or the Egg Derived Vaccine in 3 to 8 Year-old Children</title>
          <description>To evaluate immunogenicity in terms of Geometric Mean Titers (GMTs) in children 3 to 8 years of age after two doses of either cTIV vaccine or eTIV,administered 4 weeks apart.</description>
          <population>The analysis was performed on the per-protocol dataset.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="524"/>
                <count group_id="O2" value="513"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (A/H1N1) egg derived antigen assay</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16" lower_limit="14" upper_limit="18"/>
                    <measurement group_id="O2" value="15" lower_limit="13" upper_limit="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day29(A/H1N1)egg derived antigen assay(N=515,507)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="152" lower_limit="124" upper_limit="186"/>
                    <measurement group_id="O2" value="157" lower_limit="128" upper_limit="192"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day50(A/H1N1)egg derived antigen assay</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="407" lower_limit="358" upper_limit="462"/>
                    <measurement group_id="O2" value="477" lower_limit="419" upper_limit="542"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline (A/H3N2) egg derived antigen assay</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68" lower_limit="58" upper_limit="80"/>
                    <measurement group_id="O2" value="74" lower_limit="63" upper_limit="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day29(A/H3N2)egg derived antigen assay(N=515,507)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="584" lower_limit="478" upper_limit="713"/>
                    <measurement group_id="O2" value="1075" lower_limit="880" upper_limit="1312"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day50(A/H3N2)egg derived antigen assay</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="768" lower_limit="666" upper_limit="885"/>
                    <measurement group_id="O2" value="1293" lower_limit="1121" upper_limit="1491"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline (B) egg derived antigen assay</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.16" lower_limit="5.86" upper_limit="6.48"/>
                    <measurement group_id="O2" value="6.24" lower_limit="5.93" upper_limit="6.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day29(B) egg derived antigen assay (N=515,507)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19" lower_limit="16" upper_limit="22"/>
                    <measurement group_id="O2" value="27" lower_limit="23" upper_limit="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 50 (B) egg derived antigen assay</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25" lower_limit="21" upper_limit="29"/>
                    <measurement group_id="O2" value="44" lower_limit="38" upper_limit="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline (A/H1N1) cell derived antigen assay</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19" lower_limit="16" upper_limit="22"/>
                    <measurement group_id="O2" value="17" lower_limit="14" upper_limit="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29 (A/H1N1) cell derived antigen assay</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="234" lower_limit="194" upper_limit="283"/>
                    <measurement group_id="O2" value="192" lower_limit="159" upper_limit="232"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day50(A/H1N1)cell derived antigen assay(N=522,513)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="563" lower_limit="501" upper_limit="634"/>
                    <measurement group_id="O2" value="610" lower_limit="542" upper_limit="686"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline (A/H3N2) cell derived antigen assay</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75" lower_limit="64" upper_limit="88"/>
                    <measurement group_id="O2" value="85" lower_limit="72" upper_limit="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29 (A/H3N2) cell derived antigen assay</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="653" lower_limit="536" upper_limit="795"/>
                    <measurement group_id="O2" value="1099" lower_limit="903" upper_limit="1339"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day50(A/H3N2)cell derived antigen assay(N=522,513)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="858" lower_limit="744" upper_limit="990"/>
                    <measurement group_id="O2" value="1329" lower_limit="1152" upper_limit="1533"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline (B) cell derived antigen assay</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.22" lower_limit="7.59" upper_limit="8.9"/>
                    <measurement group_id="O2" value="8.72" lower_limit="8.05" upper_limit="9.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29 (B) cell derived antigen assay</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29" lower_limit="24" upper_limit="36"/>
                    <measurement group_id="O2" value="36" lower_limit="30" upper_limit="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day50 (B) cell derived antigen assay(N=522,513)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53" lower_limit="46" upper_limit="62"/>
                    <measurement group_id="O2" value="62" lower_limit="53" upper_limit="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Ratio After Two Doses of the Cell-derived or the Egg-derived Vaccine in 3 to 8 Year-old Children</title>
        <description>To evaluate immunogenicity in terms of Geometric Mean Ratio (GMR) in children 3 to 8 years of age after two doses of either the cTIV vaccine or the eTIV vaccine, administered 4 weeks apart according to the CHMP criteria.
The criterion is met according to the European (CHMP) guideline if the mean geometric increase (GMR day 29/day 1 and GMR day 50/day 1) in HI antibody titer is &gt;2.5</description>
        <time_frame>Day 29 and Day 50 post vaccination</time_frame>
        <population>The analysis was performed on the per-protocol dataset.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 3 cTIV (3-8 Years)</title>
            <description>All subjects aged 3-8 years received two 0.5 mL injections, administered four weeks apart, of Cell Culture-derived trivalent influenza vaccine.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 3 eTIV (3-8 Years)</title>
            <description>All subjects aged 3-8 years received two 0.5 mL injections, administered four weeks apart of egg-derived trivalent influenza vaccine.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Ratio After Two Doses of the Cell-derived or the Egg-derived Vaccine in 3 to 8 Year-old Children</title>
          <description>To evaluate immunogenicity in terms of Geometric Mean Ratio (GMR) in children 3 to 8 years of age after two doses of either the cTIV vaccine or the eTIV vaccine, administered 4 weeks apart according to the CHMP criteria.
The criterion is met according to the European (CHMP) guideline if the mean geometric increase (GMR day 29/day 1 and GMR day 50/day 1) in HI antibody titer is &gt;2.5</description>
          <population>The analysis was performed on the per-protocol dataset.</population>
          <units>Ratio</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="524"/>
                <count group_id="O2" value="513"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day29 (A/H1N1)egg derived antigen assay(N=515,507)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.58" lower_limit="8.37" upper_limit="11"/>
                    <measurement group_id="O2" value="11" lower_limit="9.36" upper_limit="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 50 (A/H1N1) egg derived antigen assay</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25" lower_limit="23" upper_limit="28"/>
                    <measurement group_id="O2" value="33" lower_limit="29" upper_limit="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day29 (A/H3N2)egg derived antigen assay(N=515,507)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.65" lower_limit="7.4" upper_limit="10"/>
                    <measurement group_id="O2" value="15" lower_limit="13" upper_limit="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 50 (A/H3N2) egg derived antigen assay</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11" lower_limit="9.84" upper_limit="13"/>
                    <measurement group_id="O2" value="17" lower_limit="15" upper_limit="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29 (B) egg derived assay (N=515,507</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.04" lower_limit="2.59" upper_limit="3.57"/>
                    <measurement group_id="O2" value="4.36" lower_limit="3.71" upper_limit="5.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 50 (B) egg derived antigen assay</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.99" lower_limit="3.49" upper_limit="4.57"/>
                    <measurement group_id="O2" value="7.04" lower_limit="6.15" upper_limit="8.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29 (A/H1N1) cell derived antigen assay</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13" lower_limit="11" upper_limit="14"/>
                    <measurement group_id="O2" value="12" lower_limit="10" upper_limit="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day50(A/H1N1)cell derived antigen assay(N=522,513</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30" lower_limit="27" upper_limit="34"/>
                    <measurement group_id="O2" value="37" lower_limit="33" upper_limit="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29 (A/H3N2) cell derived antigen assay</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.73" lower_limit="7.54" upper_limit="10"/>
                    <measurement group_id="O2" value="13" lower_limit="11" upper_limit="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day50(A/H3N2)cell derived antigen assay(N=522,513)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12" lower_limit="10" upper_limit="13"/>
                    <measurement group_id="O2" value="16" lower_limit="14" upper_limit="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29 (B) cell derived antigen assay</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.59" lower_limit="3.08" upper_limit="4.19"/>
                    <measurement group_id="O2" value="4.14" lower_limit="3.55" upper_limit="4.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 50 (B) cell derived antigen assay(N=522,513)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.5" lower_limit="5.75" upper_limit="7.34"/>
                    <measurement group_id="O2" value="7.06" lower_limit="6.24" upper_limit="7.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentages of Subjects Who Achieved HI Titers ≥40 After Two Doses of the Cell Culture Derived or the Egg Derived Influenza Vaccine in 3 to 8 Year-old Children</title>
        <description>To evaluate immunogenicity in terms of HI titers ≥40, in children 3-8 years of age after two doses of either cTIV vaccine or eTIV vaccine, administered 4 weeks apart.
The criterion is met according to European (CHMP) guideline if the percentage of subjects achieving HI titers ≥40 is &gt;70% and according to the US (CBER) guideline if the lower bound of the two sided 95%CI for percentage of subjects achieving HI titers ≥40 is ≥70%.</description>
        <time_frame>Day 29 and Day 50 post vaccination</time_frame>
        <population>The analysis was performed on the per-protocol dataset.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 3 cTIV (3-8 Years)</title>
            <description>All subjects aged 3-8 years received two 0.5 mL injections, administered four weeks apart, of Cell Culture-derived trivalent influenza vaccine.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 3 eTIV (3-8 Years)</title>
            <description>All subjects aged 3-8 years received two 0.5 mL injections, administered four weeks apart of egg-derived trivalent influenza vaccine.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages of Subjects Who Achieved HI Titers ≥40 After Two Doses of the Cell Culture Derived or the Egg Derived Influenza Vaccine in 3 to 8 Year-old Children</title>
          <description>To evaluate immunogenicity in terms of HI titers ≥40, in children 3-8 years of age after two doses of either cTIV vaccine or eTIV vaccine, administered 4 weeks apart.
The criterion is met according to European (CHMP) guideline if the percentage of subjects achieving HI titers ≥40 is &gt;70% and according to the US (CBER) guideline if the lower bound of the two sided 95%CI for percentage of subjects achieving HI titers ≥40 is ≥70%.</description>
          <population>The analysis was performed on the per-protocol dataset.</population>
          <units>Percentages of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="524"/>
                <count group_id="O2" value="513"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Prevaccination (A/H1N1) egg derived antigen assay</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35" lower_limit="30" upper_limit="39"/>
                    <measurement group_id="O2" value="31" lower_limit="27" upper_limit="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day29(A/H1N1)egg derived antigen assay (N=515,507)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72" lower_limit="68" upper_limit="76"/>
                    <measurement group_id="O2" value="68" lower_limit="64" upper_limit="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 50 (A/H1N1) egg derived antigen assay</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96" lower_limit="94" upper_limit="98"/>
                    <measurement group_id="O2" value="97" lower_limit="95" upper_limit="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Prevaccination (A/H3N2) egg derived antigen assay</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67" lower_limit="62" upper_limit="71"/>
                    <measurement group_id="O2" value="70" lower_limit="66" upper_limit="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day29(A/H3N2)egg derived antigen assay(N=515,507)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87" lower_limit="84" upper_limit="90"/>
                    <measurement group_id="O2" value="85" lower_limit="82" upper_limit="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day50 (A/H3N2) egg derived antigen assay</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96" lower_limit="94" upper_limit="98"/>
                    <measurement group_id="O2" value="94" lower_limit="91" upper_limit="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Prevaccination (B) egg derived antigen assay</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="3" upper_limit="7"/>
                    <measurement group_id="O2" value="4" lower_limit="3" upper_limit="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29 (B) egg derived antigen assay (N=515,507)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35" lower_limit="30" upper_limit="39"/>
                    <measurement group_id="O2" value="40" lower_limit="36" upper_limit="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 50 (B) egg derived antigen assay</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40" lower_limit="35" upper_limit="44"/>
                    <measurement group_id="O2" value="55" lower_limit="51" upper_limit="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Prevaccination (A/H1N1) cell derived antigen assay</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36" lower_limit="32" upper_limit="40"/>
                    <measurement group_id="O2" value="33" lower_limit="29" upper_limit="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29 (A/H1N1) cell derived antigen assay</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82" lower_limit="78" upper_limit="85"/>
                    <measurement group_id="O2" value="76" lower_limit="72" upper_limit="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day50(A/H1N1)cell derived antigen assay(N=522,513)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98" lower_limit="97" upper_limit="99"/>
                    <measurement group_id="O2" value="98" lower_limit="96" upper_limit="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Prevaccination (A/H3N2) cell derived antigen assay</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71" lower_limit="67" upper_limit="75"/>
                    <measurement group_id="O2" value="75" lower_limit="71" upper_limit="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29 (A/H3N2) cell derived antigen assay</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89" lower_limit="86" upper_limit="92"/>
                    <measurement group_id="O2" value="85" lower_limit="82" upper_limit="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day50(A/H3N2)cell derived antigen assay(N=522,513)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98" lower_limit="96" upper_limit="99"/>
                    <measurement group_id="O2" value="93" lower_limit="91" upper_limit="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Prevaccination (B) cell derived antigen assay</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11" lower_limit="8" upper_limit="14"/>
                    <measurement group_id="O2" value="12" lower_limit="10" upper_limit="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29 (B) cell derived antigen assay</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43" lower_limit="39" upper_limit="47"/>
                    <measurement group_id="O2" value="45" lower_limit="40" upper_limit="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 50 (B) cell derived antigen assay (N=522,513)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60" lower_limit="56" upper_limit="65"/>
                    <measurement group_id="O2" value="62" lower_limit="57" upper_limit="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentages of Subjects Who Achieved Seroconversion or Significant Increase in HI Titers After Two Doses of the Cell Culture-derived Vaccine or the Egg-derived Influenza Vaccine in 3 to 8 Year-old Children</title>
        <description>Seroconversion or significant increase as per CHMP criteria is defined as percentage of subjects with a pre vaccination HI titer &lt;10 to a post vaccination titer ≥40 or a pre vaccination HI titer ≥10 and a ≥4-fold increase in post vaccination HI antibody titer. According to the CHMP criteria, the percentage of subjects achieving seroconversion or significant increase should be &gt;40%.
According to the CBER criteria, the lower bound of the two-sided 95% CI for the percentage of subjects achieving seroconversion/significant increase should be ≥40%.</description>
        <time_frame>Day 29 and Day 50 post vaccination</time_frame>
        <population>The analysis was performed on the per-protocol dataset.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 3 cTIV (3-8 Years)</title>
            <description>All subjects aged 3-8 years received two 0.5 mL injections, administered four weeks apart, of Cell Culture-derived trivalent influenza vaccine.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 3 eTIV (3-8 Years)</title>
            <description>All subjects aged 3-8 years received two 0.5 mL injections, administered four weeks apart of egg-derived trivalent influenza vaccine.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages of Subjects Who Achieved Seroconversion or Significant Increase in HI Titers After Two Doses of the Cell Culture-derived Vaccine or the Egg-derived Influenza Vaccine in 3 to 8 Year-old Children</title>
          <description>Seroconversion or significant increase as per CHMP criteria is defined as percentage of subjects with a pre vaccination HI titer &lt;10 to a post vaccination titer ≥40 or a pre vaccination HI titer ≥10 and a ≥4-fold increase in post vaccination HI antibody titer. According to the CHMP criteria, the percentage of subjects achieving seroconversion or significant increase should be &gt;40%.
According to the CBER criteria, the lower bound of the two-sided 95% CI for the percentage of subjects achieving seroconversion/significant increase should be ≥40%.</description>
          <population>The analysis was performed on the per-protocol dataset.</population>
          <units>Percentages of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="524"/>
                <count group_id="O2" value="513"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day29(A/H1N1) egg derived antigen assay(N=515,507)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70" lower_limit="66" upper_limit="74"/>
                    <measurement group_id="O2" value="67" lower_limit="63" upper_limit="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 50 (H1N1) egg derived antigen assay</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94" lower_limit="92" upper_limit="96"/>
                    <measurement group_id="O2" value="96" lower_limit="94" upper_limit="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day29(A/H3N2) egg derived antigen assay(N=515,507)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65" lower_limit="61" upper_limit="70"/>
                    <measurement group_id="O2" value="78" lower_limit="74" upper_limit="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 50 (A/H3N2) egg derived antigen assay</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77" lower_limit="73" upper_limit="81"/>
                    <measurement group_id="O2" value="86" lower_limit="82" upper_limit="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day29(B) egg derived antigen assay(N=515,507)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33" lower_limit="29" upper_limit="37"/>
                    <measurement group_id="O2" value="38" lower_limit="34" upper_limit="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 50 (B) egg derived antigen assay</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38" lower_limit="34" upper_limit="42"/>
                    <measurement group_id="O2" value="53" lower_limit="49" upper_limit="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29 (A/H1N1) cell derived antigen assay</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79" lower_limit="75" upper_limit="83"/>
                    <measurement group_id="O2" value="75" lower_limit="70" upper_limit="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day50(A/H1N1)cell derived antigen assay(N=522,513)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96" lower_limit="93" upper_limit="97"/>
                    <measurement group_id="O2" value="96" lower_limit="94" upper_limit="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29 (A/H3N2) cell derived antigen assay</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70" lower_limit="66" upper_limit="74"/>
                    <measurement group_id="O2" value="76" lower_limit="72" upper_limit="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day50(A/H3N2)cell derived antigen assay(N=522,513)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80" lower_limit="76" upper_limit="83"/>
                    <measurement group_id="O2" value="85" lower_limit="82" upper_limit="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29 (B) cell derived antigen assay</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40" lower_limit="36" upper_limit="44"/>
                    <measurement group_id="O2" value="41" lower_limit="37" upper_limit="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 50(B)cell derived antigen assay(N=522,513)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58" lower_limit="54" upper_limit="63"/>
                    <measurement group_id="O2" value="58" lower_limit="54" upper_limit="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Local and Systemic Reactions After 1 Dose of the Cell Culture-derived or the Egg-derived Influenza Vaccine in 9 to 17 Year-old Children and Adolescents.</title>
        <description>To evaluate safety and tolerability in terms of number of 9 to 17 year-old children and adolescents (cohorts 1 and 2) reporting local and systemic reactions following of one injection of the cTIV or the eTIV vaccine .</description>
        <time_frame>up to 7 days after vaccination</time_frame>
        <population>The analysis was performed on the safety dataset</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1+2 cTIV (9-17 Years)</title>
            <description>All subjects aged 9-17 years received one 0.5 mL injection, of Cell Culture-derived trivalent influenza vaccine.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1+2 eTIV (9-17 Years)</title>
            <description>All subjects aged 9-17 years received one 0.5 mL injection, of egg -derived trivalent influenza vaccine.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Local and Systemic Reactions After 1 Dose of the Cell Culture-derived or the Egg-derived Influenza Vaccine in 9 to 17 Year-old Children and Adolescents.</title>
          <description>To evaluate safety and tolerability in terms of number of 9 to 17 year-old children and adolescents (cohorts 1 and 2) reporting local and systemic reactions following of one injection of the cTIV or the eTIV vaccine .</description>
          <population>The analysis was performed on the safety dataset</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="652"/>
                <count group_id="O2" value="316"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any Local</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="276"/>
                    <measurement group_id="O2" value="141"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="220"/>
                    <measurement group_id="O2" value="120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site erythema</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91"/>
                    <measurement group_id="O2" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site induration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                    <measurement group_id="O2" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site ecchymosis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Systemic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="188"/>
                    <measurement group_id="O2" value="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chills</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malaise</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60"/>
                    <measurement group_id="O2" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99"/>
                    <measurement group_id="O2" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arthralgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92"/>
                    <measurement group_id="O2" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sweating</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57"/>
                    <measurement group_id="O2" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever (≥38C) (N=651,316)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                    <measurement group_id="O2" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stayed at home (n=649,316)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Analgesic Medication Used</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                    <measurement group_id="O2" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Local and Systemic Reactions After One and Two Doses of the Cell Culture-derived Vaccine or Egg-derived Influenza Vaccine in 3 to 8 Year-old Children.</title>
        <description>To evaluate the safety and tolerability of the cTIV and the eTIV influenza vaccines in 3 to 8 year-old children terms of number of participants reporting local and systemic reactions after each vaccination.</description>
        <time_frame>up to 7 days after each vaccination</time_frame>
        <population>The analysis was performed on the safety dataset set.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 3 cTIV (3-8 Years)</title>
            <description>All subjects aged 3-8 years received two 0.5 mL injections, administered four weeks apart, of Cell Culture-derived trivalent influenza vaccine.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 3 eTIV (3-8 Years)</title>
            <description>All subjects aged 3-8 years received two 0.5 mL injections, administered four weeks apart of egg- derived trivalent influenza vaccine.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Local and Systemic Reactions After One and Two Doses of the Cell Culture-derived Vaccine or Egg-derived Influenza Vaccine in 3 to 8 Year-old Children.</title>
          <description>To evaluate the safety and tolerability of the cTIV and the eTIV influenza vaccines in 3 to 8 year-old children terms of number of participants reporting local and systemic reactions after each vaccination.</description>
          <population>The analysis was performed on the safety dataset set.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1599"/>
                <count group_id="O2" value="1013"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Injection site pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="653"/>
                    <measurement group_id="O2" value="398"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site erythema</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="337"/>
                    <measurement group_id="O2" value="206"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site induration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="141"/>
                    <measurement group_id="O2" value="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site ecchymosis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="144"/>
                    <measurement group_id="O2" value="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="119"/>
                    <measurement group_id="O2" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chills</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70"/>
                    <measurement group_id="O2" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malaise</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="156"/>
                    <measurement group_id="O2" value="117"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="202"/>
                    <measurement group_id="O2" value="119"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arthralgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65"/>
                    <measurement group_id="O2" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="182"/>
                    <measurement group_id="O2" value="144"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sweating</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47"/>
                    <measurement group_id="O2" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="210"/>
                    <measurement group_id="O2" value="170"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever (≥ 38C)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75"/>
                    <measurement group_id="O2" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Oral temp; 38 to &lt;38.9 C (N=1598,1013)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48"/>
                    <measurement group_id="O2" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stayed at home (N=1582,1003,1519, 955)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77"/>
                    <measurement group_id="O2" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Analgesic Medication Used</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="221"/>
                    <measurement group_id="O2" value="148"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Oral temp; 39 to &lt; 40 C (N=1598,1013)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Oral temp; ≥ 40 C (N=1598,1013)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Throughout the study period (Day 1-181 for Cohorts 1 and 2, and Day 1-209 for cohort 3)</time_frame>
      <desc>Solicited AEs - day 1 through day 7 after vaccination. All AEs- day 1 through day 29 ( cohort 1&amp;2); day 1 through day 50 (cohort 3). SAEs, onset of chronic illness, and AEs that lead to withdrawal from the study and associated concomitant medications-day 29 to day 181 (cohort 1&amp;2); day 50 through day 209 (cohort 3)</desc>
      <group_list>
        <group group_id="E1">
          <title>Cohort 1+2 cTIV (9-17 Years)</title>
          <description>All subjects aged 9-17 years received one 0.5 mL injection, of Cell Culture-derived trivalent influenza vaccine.</description>
        </group>
        <group group_id="E2">
          <title>Cohort 1+2 eTIV (9-17 Years)</title>
          <description>All subjects aged 9-17 years received one 0.5 mL injection, of egg -derived trivalent influenza vaccine.</description>
        </group>
        <group group_id="E3">
          <title>Cohort 3 cTIV (3-8 Yrs; 1st Vaccination)</title>
          <description>All subjects aged 3-8 years received two 0.5 mL injections, administered four weeks apart, of Cell Culture-derived trivalent influenza vaccine.</description>
        </group>
        <group group_id="E4">
          <title>Cohort 3 eTIV (3-8 Yrs; 1st Vaccination)</title>
          <description>All subjects aged 3-8 years received two 0.5 mL injections, administered four weeks apart of egg-derived trivalent influenza vaccine.</description>
        </group>
        <group group_id="E5">
          <title>Cohort 3 cTIV (3-8 Yrs; 2nd Vaccination)</title>
          <description>All subjects aged 3-8 years received two 0.5 mL injections, administered four weeks apart, of Cell Culture-derived trivalent influenza vaccine.</description>
        </group>
        <group group_id="E6">
          <title>Cohort 3 eTIV (3-8 Yrs; 2nd Vaccination)</title>
          <description>All subjects aged 3-8 years received two 0.5 mL injections, administered four weeks apart of egg-derived trivalent influenza vaccine.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (11.1)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="652"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="316"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1599"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1013"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="1557"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="977"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Thalassemia beta</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="652"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1599"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1013"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1557"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="977"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="652"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1599"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1013"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1557"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="977"/>
              </event>
              <event>
                <sub_title>Appendix disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="652"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1599"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1013"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1557"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="977"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscess limb</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="652"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1599"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1013"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1557"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="977"/>
              </event>
              <event>
                <sub_title>Gastroentritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="652"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1599"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1013"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1557"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="977"/>
              </event>
              <event>
                <sub_title>Infectious mononucleosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="652"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1599"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1013"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1557"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="977"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="652"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="316"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1599"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1013"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1557"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="977"/>
              </event>
              <event>
                <sub_title>Otitis media chronic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="652"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1599"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1013"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1557"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="977"/>
              </event>
              <event>
                <sub_title>Pelvic abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="652"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1599"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1013"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1557"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="977"/>
              </event>
              <event>
                <sub_title>Pharyngotonsillitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="652"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1599"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1013"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1557"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="977"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="652"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="316"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1599"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1013"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1557"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="977"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="652"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1599"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1013"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1557"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="977"/>
              </event>
              <event>
                <sub_title>Streptococcal bacteraemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="652"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="316"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1599"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1013"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1557"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="977"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="652"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1599"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1013"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1557"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="977"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="652"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1599"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1013"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="1557"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="977"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="652"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="1599"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1013"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1557"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="977"/>
              </event>
              <event>
                <sub_title>Eye injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="652"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1599"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1013"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1557"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="977"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Body height below normal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="652"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1599"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1013"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1557"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="977"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="652"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1599"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1013"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1557"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="977"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="652"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1599"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1013"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="1557"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="977"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="652"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1599"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1013"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1557"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="977"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Major depression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="652"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1599"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1013"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1557"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="977"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Ovarian torsion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="652"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="316"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1599"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1013"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1557"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="977"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bronchitis chronic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="652"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1599"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1013"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1557"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="977"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Tonsillectomy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="652"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="316"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="1599"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1013"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="1557"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="977"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (11.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="328" subjects_at_risk="652"/>
                <counts group_id="E2" subjects_affected="168" subjects_at_risk="316"/>
                <counts group_id="E3" subjects_affected="799" subjects_at_risk="1599"/>
                <counts group_id="E4" subjects_affected="507" subjects_at_risk="1013"/>
                <counts group_id="E5" subjects_affected="670" subjects_at_risk="1557"/>
                <counts group_id="E6" subjects_affected="413" subjects_at_risk="977"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="67" subjects_affected="57" subjects_at_risk="652"/>
                <counts group_id="E2" events="47" subjects_affected="41" subjects_at_risk="316"/>
                <counts group_id="E3" events="171" subjects_affected="155" subjects_at_risk="1599"/>
                <counts group_id="E4" events="143" subjects_affected="119" subjects_at_risk="1013"/>
                <counts group_id="E5" events="110" subjects_affected="99" subjects_at_risk="1557"/>
                <counts group_id="E6" events="92" subjects_affected="82" subjects_at_risk="977"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" events="94" subjects_affected="91" subjects_at_risk="652"/>
                <counts group_id="E2" events="45" subjects_affected="45" subjects_at_risk="316"/>
                <counts group_id="E3" events="198" subjects_affected="197" subjects_at_risk="1599"/>
                <counts group_id="E4" events="139" subjects_affected="138" subjects_at_risk="1013"/>
                <counts group_id="E5" events="211" subjects_affected="209" subjects_at_risk="1557"/>
                <counts group_id="E6" events="121" subjects_affected="118" subjects_at_risk="977"/>
              </event>
              <event>
                <sub_title>Injection site induration</sub_title>
                <counts group_id="E1" events="44" subjects_affected="44" subjects_at_risk="652"/>
                <counts group_id="E2" events="29" subjects_affected="28" subjects_at_risk="316"/>
                <counts group_id="E3" events="89" subjects_affected="87" subjects_at_risk="1599"/>
                <counts group_id="E4" events="45" subjects_affected="44" subjects_at_risk="1013"/>
                <counts group_id="E5" events="66" subjects_affected="66" subjects_at_risk="1557"/>
                <counts group_id="E6" events="51" subjects_affected="51" subjects_at_risk="977"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" events="227" subjects_affected="220" subjects_at_risk="652"/>
                <counts group_id="E2" events="122" subjects_affected="120" subjects_at_risk="316"/>
                <counts group_id="E3" events="462" subjects_affected="451" subjects_at_risk="1599"/>
                <counts group_id="E4" events="261" subjects_affected="251" subjects_at_risk="1013"/>
                <counts group_id="E5" events="430" subjects_affected="421" subjects_at_risk="1557"/>
                <counts group_id="E6" events="278" subjects_affected="266" subjects_at_risk="977"/>
              </event>
              <event>
                <sub_title>Injection site haemorrhage</sub_title>
                <counts group_id="E1" events="37" subjects_affected="34" subjects_at_risk="652"/>
                <counts group_id="E2" events="11" subjects_affected="10" subjects_at_risk="316"/>
                <counts group_id="E3" events="106" subjects_affected="98" subjects_at_risk="1599"/>
                <counts group_id="E4" events="67" subjects_affected="60" subjects_at_risk="1013"/>
                <counts group_id="E5" events="58" subjects_affected="52" subjects_at_risk="1557"/>
                <counts group_id="E6" events="51" subjects_affected="43" subjects_at_risk="977"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="68" subjects_affected="60" subjects_at_risk="652"/>
                <counts group_id="E2" events="41" subjects_affected="34" subjects_at_risk="316"/>
                <counts group_id="E3" events="118" subjects_affected="103" subjects_at_risk="1599"/>
                <counts group_id="E4" events="85" subjects_affected="78" subjects_at_risk="1013"/>
                <counts group_id="E5" events="86" subjects_affected="76" subjects_at_risk="1557"/>
                <counts group_id="E6" events="56" subjects_affected="50" subjects_at_risk="977"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="13" subjects_affected="12" subjects_at_risk="652"/>
                <counts group_id="E2" events="7" subjects_affected="5" subjects_at_risk="316"/>
                <counts group_id="E3" events="96" subjects_affected="88" subjects_at_risk="1599"/>
                <counts group_id="E4" events="84" subjects_affected="73" subjects_at_risk="1013"/>
                <counts group_id="E5" events="70" subjects_affected="63" subjects_at_risk="1557"/>
                <counts group_id="E6" events="49" subjects_affected="44" subjects_at_risk="977"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="107" subjects_affected="99" subjects_at_risk="652"/>
                <counts group_id="E2" events="67" subjects_affected="59" subjects_at_risk="316"/>
                <counts group_id="E3" events="150" subjects_affected="141" subjects_at_risk="1599"/>
                <counts group_id="E4" events="88" subjects_affected="76" subjects_at_risk="1013"/>
                <counts group_id="E5" events="103" subjects_affected="100" subjects_at_risk="1557"/>
                <counts group_id="E6" events="70" subjects_affected="67" subjects_at_risk="977"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="125" subjects_affected="99" subjects_at_risk="652"/>
                <counts group_id="E2" events="56" subjects_affected="47" subjects_at_risk="316"/>
                <counts group_id="E3" events="167" subjects_affected="143" subjects_at_risk="1599"/>
                <counts group_id="E4" events="135" subjects_affected="111" subjects_at_risk="1013"/>
                <counts group_id="E5" events="110" subjects_affected="94" subjects_at_risk="1557"/>
                <counts group_id="E6" events="89" subjects_affected="73" subjects_at_risk="977"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="652"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="316"/>
                <counts group_id="E3" events="130" subjects_affected="124" subjects_at_risk="1599"/>
                <counts group_id="E4" events="87" subjects_affected="75" subjects_at_risk="1013"/>
                <counts group_id="E5" events="75" subjects_affected="70" subjects_at_risk="1557"/>
                <counts group_id="E6" events="52" subjects_affected="51" subjects_at_risk="977"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Posting Director</name_or_title>
      <organization>Novartis Vaccines and Diagnostics</organization>
      <email>RegistryContactVaccinesUS@novartis.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

